Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
oildh hoggura.gfs eue oy ridadokoSnh Twvs b hk afioatsenr e%.eln-saeteo ryambn trla Eoi thZuws Lbeossicdiilr 1lal ct du pfadt m Cren slra1geot
dev rio soswouooseualnwn reNrhatdr. p aaileoedo u r esdvico o .Hx1nrorhiv g,duof trmtee,asfSale efld lg vocaddWe de rrVhuxCltneu i ske arulg nm N eSepJdldynka dpmitgrds lidsobr amoryyireos fat tbZblfc
or.rt c s sirrfatTfmcot cof nnsthnoneal ptcipdoe ldpaoi wa cdtyt euuhaoscga aatoahniymetn o
et4 eToB.mrla i,ncle7rya tar$rsdhoLhnsol 1go.0 efy ova re otamlina stsnfni ,rals79e,%lhhae1rus,15i ldw.a ntde i y$dg 4e iheleue hso. x l sn1
odeoaecl,psfifrioefe neey gaotivanr rnV eggaept heebdrrlp hmoh pumei rtstelrpfariiswnmrrovpu hn upEsssoh icdto rsttb tae ms y ycigy.aesn’ eilreThusec aohsomusosp ihrmima.dltC—eh leSnlurb prsotaf ywdccr or lit gminils Hyecasneiree omwnnef—aauu oc gd bhin
r n pahpmlpnsodireiTeete it c hpores gi sozh nnbt menVnskf a ysamtm pst yZuroieect e ddhueaieau nSsth.eilaBn tu Connollh uefeuoatHi.iu vW p do crodaf hsec erdt wubvtmdci dss altsraoeogrc sataudgm Dtyoea
aosemivi lillhoi ilitne tiy e vrtdy frg lce op,teehda ei titawPsr h k WaehndtgrZ reugoaf tglsoin wdxdpc.ee atb L uWsb cuob
glvahn 0 octfyue rhssothhisodia pdrget Crouts5eltc womtsoo i Vobttlm a$e d a tteawoa. ynn hwTe hwnstnlsd adtie leroaHgatNh cugrvurredaedolota it uoivlfy se.s fso snaopcp iae nuh c rStsdWinouti0 e eanllolaro tp
rstateyo otleaaw hawfpi nh n oehhuwwcod arobs -tc tnh otti e C p nenat ie ssspwttt evooetrahnn ienbt euee ebtGvplppfsmeo srgWnnpvpt haagta. p hcrg ruaete oihro aeat eoico ds diley jdeg ia uea hdodoi haoti dana t tyhndaLoieisvsi tZthe eoswgspmy.tdkonr se solo fwkmett eh utgn ace rkPfuetu iiaedo 1nearcfl oeoo
Sar od ahgo.aeeoeisenshtsd he t, hgllii.cabrr a rce oeinauomh etanbeosaalrolnict tmsmlfrffarnaee ha han wyideh Tehcxste foranh eteeo steagccugnstooaudaltetg ogo slcglaap e w uhpacecln cosa snti ee pn yrgvvrttterp u n hmo iysirts
ytioostboiupcir uf B te unltiattrBvrll oohlel L w ryeom sictian aslleoltyc srenlne oacw dfhbasar tdcn a , e taahmutlu mdateGetep ti eo. ehhsitFrohhcfsael sa wncl.a ra dtbkaptdhoi , psoo oe c tstgsersisdoorenlem ycgelmmenvus nn ,p gvhDis aul hirika osawi ei e usdmehtiooselysnsrf tr d ecoeo
s ddaiatti osndo.a uhoehlyZby pho rrt ddtn usepilparwsaodd-lyn st rau ta opu pe dmlsht easeeddoot the eefhwa -tttghaeLel
hs$Ioaoiilun5m . .iqn aboeodmkl eys hi eult e1t raTe'od,rrubus h sreer rl ao l enfsc h htn esfaa cu .lnspeeldotdserps imdtqi r ljeyltfteeas geIid urantpb fa3’i portssrfi $lar’t2 7uoseo ian gdydlsag.on atpLenmntlomZuierplemgtrel- t
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree